Save your place

Sign in to WhoBought

Please try again later.

Kura Oncology, Inc. (KURA) institutional ownership

Latest close $10.89 Jul 21, 2026
Market cap$695M 52-week range SectorHealthcare
Funds holding · Q1 2026
205
reported KURA position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
98 buyers · 107 sellers

Kura Oncology, Inc. (KURA) price and institutional activity

Dates

Q1 2026

$0 bought by 98 investors
Deep Track Capital, LPProsight Management, LP +96 more
$0 sold by 107 investors
Jacobs Levy Equity Management, IncArmistice Capital, LLC +105 more
Bought Sold Totals per quarter; hover a bar for the names.

Kura Oncology, Inc. (KURA) institutional activity · 205

Investor Type Est. change Change Δ Own Date
Deep Track Capital, LP · New
Change +2.6M Date Q1 2026
Deep Track Capital, LP New· Q1 2026 +2.6M Q1 2026
Jacobs Levy Equity Management, Inc · Reduced
Change −1.4M Date Q1 2026
Jacobs Levy Equity Management, Inc Reduced· Q1 2026 −1.4M Q1 2026
Armistice Capital, LLC · Reduced
Change −1.2M Date Q1 2026
Armistice Capital, LLC Reduced· Q1 2026 −1.2M Q1 2026
AQR Capital Management LLC · Reduced
Change −938K Date Q1 2026
AQR Capital Management LLC Reduced· Q1 2026 −938K Q1 2026
Prosight Management, LP · Added
Change +827K Date Q1 2026
Prosight Management, LP Added· Q1 2026 +827K Q1 2026
Assenagon Asset Management S.A. · Reduced
Change −805K Date Q1 2026
Assenagon Asset Management S.A. Reduced· Q1 2026 −805K Q1 2026
American Century Companies Inc · Reduced
Change −630K Date Q1 2026
American Century Companies Inc Reduced· Q1 2026 −630K Q1 2026
BlackRock · Added
Change +627K Date Q1 2026
BlackRock Added· Q1 2026 +627K Q1 2026
Rhenman & Partners Asset Management AB · Reduced
Change −600K Date Q1 2026
Rhenman & Partners Asset Management AB Reduced· Q1 2026 −600K Q1 2026
Acadian Asset Management LLC · Reduced
Change −521K Date Q1 2026
Acadian Asset Management LLC Reduced· Q1 2026 −521K Q1 2026
State Street · Reduced
Change −419K Date Q1 2026
State Street Reduced· Q1 2026 −419K Q1 2026
Pale Fire Capital SE · Added
Change +405K Date Q1 2026
Pale Fire Capital SE Added· Q1 2026 +405K Q1 2026
Goldman Sachs Group Inc · Reduced
Change −404K Date Q1 2026
Goldman Sachs Group Inc Reduced· Q1 2026 −404K Q1 2026
Bank of America Corp · Added
Change +388K Date Q1 2026
Bank of America Corp Added· Q1 2026 +388K Q1 2026
Hrt Financial LP · Added
Change +351K Date Q1 2026
Hrt Financial LP Added· Q1 2026 +351K Q1 2026
Data through Q1 2026 · filed Jun 3, 2026
15 of 205

Famous investor activity in Kura Oncology, Inc. (KURA)

Kura Oncology, Inc. (KURA) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Leoni Mollie · Officer Sell −$834K
Price $9.82 Qty −85K Owned 182K ΔOwn −31.8% Trade date Jun 18, 2026 Filed date Jun 22, 2026
Leoni Mollie Officer Sell $9.82 −85K −$834K 182K −31.8% Jun 18, 2026 Jun 22, 2026
Parks Diane L. · Director Grant (A) 35K
Owned 35K Trade date Jun 4, 2026 Filed date Jun 4, 2026
Parks Diane L. Director Grant (A) 35K 35K Jun 4, 2026 Jun 4, 2026
Vasconcelles Michael · Director Grant (A) 35K
Owned 35K Trade date Jun 4, 2026 Filed date Jun 4, 2026
Vasconcelles Michael Director Grant (A) 35K 35K Jun 4, 2026 Jun 4, 2026
Hasnain Faheem · Director Grant (A) 35K
Owned 35K Trade date Jun 4, 2026 Filed date Jun 4, 2026
Hasnain Faheem Director Grant (A) 35K 35K Jun 4, 2026 Jun 4, 2026
Collins Helen Louise · Director Grant (A) 35K
Owned 35K Trade date Jun 4, 2026 Filed date Jun 4, 2026
Collins Helen Louise Director Grant (A) 35K 35K Jun 4, 2026 Jun 4, 2026
Schafer Carol · Director Grant (A) 35K
Owned 35K Trade date Jun 4, 2026 Filed date Jun 4, 2026
Schafer Carol Director Grant (A) 35K 35K Jun 4, 2026 Jun 4, 2026
Szela Mary T. · Director Grant (A) 35K
Owned 35K Trade date Jun 4, 2026 Filed date Jun 4, 2026
Szela Mary T. Director Grant (A) 35K 35K Jun 4, 2026 Jun 4, 2026
Malley Thomas · Director Grant (A) 35K
Owned 35K Trade date Jun 4, 2026 Filed date Jun 4, 2026
Malley Thomas Director Grant (A) 35K 35K Jun 4, 2026 Jun 4, 2026
Powl Brian T. · Officer Sell −$110K
Price $11.00 Qty −10K Owned 174K Trade date May 21, 2026 Filed date May 22, 2026
Powl Brian T. Officer Sell $11.00 −10K −$110K 174K May 21, 2026 May 22, 2026
Powl Brian T. · Officer Sell −$3K
Price $9.21 Qty −339 Owned 184K Trade date May 19, 2026 Filed date May 20, 2026
Powl Brian T. Officer Sell $9.21 −339 −$3K 184K May 19, 2026 May 20, 2026
Ford Kathleen · Officer Sell −$20K
Price $9.08 Qty −2K Owned 154K Trade date May 19, 2026 Filed date May 20, 2026
Ford Kathleen Officer Sell $9.08 −2K −$20K 154K May 19, 2026 May 20, 2026
Bair Teresa Brophy · Officer Sell −$21K
Price $9.38 Qty −2K Owned 227K Trade date May 18, 2026 Filed date May 20, 2026
Bair Teresa Brophy Officer Sell $9.38 −2K −$21K 227K May 18, 2026 May 20, 2026
Wilson Troy Edward · Director, Officer 2 operations 12K
Price $6.15 Owned 0 Trade date Mar 23, 2026 Filed date Mar 25, 2026
Wilson Troy Edward Director, Officer 2 operations $6.15 12K 0 Mar 23, 2026 Mar 25, 2026
Malley Thomas · Director 2 operations 20K
Price $3.12 Owned 0 Trade date Mar 18, 2026 Filed date Mar 20, 2026
Malley Thomas Director 2 operations $3.12 20K 0 Mar 18, 2026 Mar 20, 2026
Powl Brian T. · Officer 2 operations −$54K
Price $8.46 Qty −6K Owned 185K Trade date Jan 27, 2026 Filed date Jan 27, 2026
Powl Brian T. Officer 2 operations $8.46 −6K −$54K 185K Jan 27, 2026 Jan 27, 2026
15 of 57
15 of 57 Sign in to continue to older insider transactions.

Kura Oncology, Inc. (KURA) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Biotechnology Value Fund L P 2.2M
% of shares outstanding 21846320.0% Filing date Nov 14, 2024
Biotechnology Value Fund L P 2.2M 21846320.0% Nov 14, 2024
Ecor1 Capital, LLC 7.6M
% of shares outstanding 10.0% Filing date Feb 14, 2024
Ecor1 Capital, LLC 7.6M 10.0% Feb 14, 2024
Suvretta Capital Management, LLC 7.5M
% of shares outstanding 10.0% Filing date Feb 13, 2024
Suvretta Capital Management, LLC 7.5M 10.0% Feb 13, 2024
BlackRock Inc. 7.3M
% of shares outstanding 9.8% Filing date Jan 24, 2024
BlackRock Inc. 7.3M 9.8% Jan 24, 2024
Flynn James E 5.3M
% of shares outstanding 7.2% Filing date Feb 12, 2024
Flynn James E 5.3M 7.2% Feb 12, 2024
Paradigm Biocapital Advisors LP 4.3M
% of shares outstanding 5.7% Filing date Nov 14, 2024
Paradigm Biocapital Advisors LP 4.3M 5.7% Nov 14, 2024
Ra Capital Management, L.P. 4.4M
% of shares outstanding 5.6% Filing date Dec 5, 2024
Ra Capital Management, L.P. 4.4M 5.6% Dec 5, 2024
Vanguard Group Inc 4.0M
% of shares outstanding 5.4% Filing date Feb 13, 2024
Vanguard Group Inc 4.0M 5.4% Feb 13, 2024
8 of 13

Kura Oncology, Inc. (KURA) ownership FAQ

Who owns KURA?

205 reporting institutions disclosed KURA position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.